Roivant Sciences Ltd at Credit Suisse Healthcare Conference Transcript
Hello, everyone. Good afternoon. My name is Peter Crane. I'm with the Banking team here at Credit Suisse. I'm here to introduce to you, Richard Pulik. Richard Pulik is the CFO of Roivant. He's been a colleague, good friend of mine since first year at Roivant. So thank you, Richard, for coming to speak to us, and please take it away.
Thank you so much, and thank you to the Credit Suisse team for the invitation. I just wanted to take you through a few updates. I think, obviously, as you've seen, we adjusted a -- so at first, I want to just point out the disclaimer and the -- around some of the forward-looking statements on Page 2. I just wanted to level that sort of Roivant and who we are? I think the mission and vision of the company is really to redefine a big pharma from end to end. As you can see, the company has had 6 FDA approvals from Vants launched by Roivant and it's 8 year history. I think that's pretty incredible for a fairly young company. We've had 8 consecutive positive Phase III trials, and we had our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
